Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset NGVT

Coverage 92,261 Raw stories ingested 7,951 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,727 Assets with fetched stories

Cryptocurrencies BTC 4,245 ETH 3,075 SOL 1,750 XRP 1,686 USDC 965 HYPE 822

Stocks SPCX 879 MU 723 NVDA 684 MSFT 557 GOOGL 530 TSLA 504

Commodities GOLD 159 SILVER 93 OIL 51 PLATINUM 5 PALLADIUM 2 COPPER 1

Forex EURUSD 147 GBPUSD 143 USDCAD 51 USDJPY 37 AUDUSD 33 NZDUSD 23

1,679 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 44s ago
FMP Forex News Fetch every 5 min 1m ago
CoinGecko News Fetch every 5 min 1m ago
FIO Stock News Fetch every 10 min 44s ago
Patria Stock News Fetch every 10 min 44s ago
Editorial rewrite Rewrite every minute 44s ago
Asset sync Assets every 1 hour 10m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-07-17 17:50 8d ago Published 2026-07-17 12:11 8d ago	Ingevity získala v Německu schválení pro Evotherm P35 Ingevity získala od BASt schválení pro Evotherm P35 k použití v teplé asfaltové směsi v Německu. Testy potvrdily odolnost a dlouhodobý výkon v reálných podmínkách. NGVT Ingevity	FMP Stock News	78
Original source text Key Takeaways Ingevity's Evotherm P35 gained BASt approval for warm-mix asphalt use in Germany.Years of testing confirmed the product's durability and long-term performance under real-world conditions.Bio-based materials support performance and environmental goals in pavement applications. Ingevity Corporation (NGVT - Free Report) announced that its Evotherm P35 warm-mix additive has received approval from BASt, Germany's Federal Highway Research Institute, indicating that it meets the institute’s stringent quality standards. The approval allows the additive to be used in warm-mix asphalt applications and validates it for use in one of Europe's most demanding regulatory environments. The approval follows several years of technical evaluation, performance testing and comparison with conventional hot-mix asphalt. The testing was conducted under real-world traffic and environmental conditions. The results met BASt's durability and long-term performance standards required for use on federal projects in Germany. The certification strengthens Ingevity's position in the European pavement technologies market, where regulatory requirements for infrastructure materials are particularly demanding. It also demonstrates the company's ability to tailor its technologies to meet regional specifications while maintaining high performance standards. Evotherm P35 aligns with Germany's performance, environmental and regulatory priorities, highlighting the company’s formulation expertise and capability to satisfy complex technical requirements. Evotherm P35 incorporates bio-based materials designed to improve performance while supporting environmental objectives, reinforcing the company's Pavement Technologies business. NGVT’s shares have gained 62.8% over the past year compared with the industry’s 3.2% growth. Image Source: Zacks Investment Research NGVT’s Zacks Rank & Key PicksIngevity currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the Basic Materials space are Kronos Worldwide, Inc. (KRO - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Albemarle Corporation (ALB - Free Report) . While KRO and CRS currently sport a Zacks Rank #1 (Strong Buy) each, ALB carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for KRO’s 2026 loss is pinned at 33 cents per share, indicating a 65.63% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in one of the trailing four quarters and missed the remaining three. KROshares have gained 7.1% over the past year. The Zacks Consensus Estimate for CRS’ 2026 earnings is pegged at $10.56 per share, indicating a rise of 41.18% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.95%. The Zacks Consensus Estimate for ALB’s current fiscal-year earnings is pinned at $13.06 per share, indicating a 1,753% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 74.5%. ALB’s shares have gained 55% over the past year.
	Saved 2026-07-07 17:58 18d ago Published 2026-07-07 12:31 18d ago	Akcie Ingevity letos vzrostly díky prodeji aktiv a hybridům Akcie Ingevity letos vzrostly o 24,8 % a překonaly 18,1% růst odvětví díky prodeji aktiv, akvizicím a vyšší poptávce po hybridech. Prodej Ozark Road Markings přinesl zhruba 65 mil. USD. NGVT Ingevity	FMP Stock News	72
Original source text Key Takeaways Ingevity shares have surged 24.8% YTD, outperforming the specialty chemicals industry's 18.1% gain.NGVT is streamlining via divestitures, acquisitions and cost cuts to improve margins and earnings quality.NGVT benefits from hybrid demand, boosting activated carbon sales and Performance Materials growth. Ingevity Corporation (NGVT - Free Report) shares have rallied 24.8% year to date. The company has also outperformed the Zacks Chemical - Specialty industry’s 18.1% growth over the same time frame. The rally has been driven by Ingevity's successful portfolio optimization strategy, improving demand for higher-value hybrid vehicle applications and pricing actions that have strengthened earnings growth and reinforced confidence in the company’s long-term growth outlook. Image Source: Zacks Investment Research Let’s take a look at the factors that are driving NGVT stock. Portfolio Optimization & Hybrid Vehicle Demand Drive GrowthIngevity is benefiting from its ongoing portfolio optimization and simplification strategy, which is aimed at sharpening its focus on higher-margin businesses and improving overall earnings quality. The company has made significant progress by divesting its Industrial Specialties business, Ozark Materials Road Markings product line and crude tall oil refinery, while continuing the divestiture process for its Advanced Polymer Technologies business. The company has recently completed the sale of its Ozark Road Markings business for approximately $65 million as part of these initiatives. Additionally, value-creating acquisitions such as Georgia-Pacific’s pine chemicals business have driven earnings and revenue growth. The company has also undertaken actions to lower costs and boost profitability. The ability of NGVT to offset inflation through pricing power also enabled solid financial results despite an uncertain macroeconomic environment. Alongside the portfolio transformation actions, Ingevity is benefiting from the adoption of hybrid vehicles. Following the expiration of EV tax credits, consumer preference has shifted toward hybrids, which has increased the long-term role of advanced and higher-value activated carbon solutions. This favorable product mix, combined with pricing actions, drove higher sales and stronger margins in Ingevity’s strongest segment, Performance Materials. Management also expects the transition toward hybrids to become a broader global trend, creating a long-term growth opportunity for its high-margin Performance Materials business. Together, the company's strategic portfolio optimization and increasing exposure to higher-value hybrid vehicle applications position it for stronger earnings growth, improved profitability and sustainable shareholder value creation. NGVT’s Zacks Rank & Other Key PicksNGVT currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the Basic Materials space are Albemarle Corporation (ALB - Free Report) , Carpenter Technology Corporation (CRS - Free Report) and Avino Silver & Gold Mines Ltd. (ASM - Free Report) . While ALB sports a Zacks Rank #1 (Strong Buy) at present, CRS and ASM carry a Zacks Rank #2 each. You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for ALB’s 2026 earnings is pinned at $12.98 per share, indicating a 1,743.04% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed one, with an average surprise of 74.5%. ALB’s shares have jumped 90.5% over the past year. The Zacks Consensus Estimate for CRS’ 2026 earnings is pegged at $10.56 per share, indicating a rise of 41.18% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 8.95%. The Zacks Consensus Estimate for ASM’s current fiscal-year earnings is pinned at 34 cents per share, indicating a 17.24% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 125%. ASM’sshares have gained 86.4% over the past year.